NEW YORK (GenomeWeb News) - Illumina and ReaMetrix plan to develop molecular diagnostic panels for several diseases, the companies said today.

 
The panels will "help predict the risk of disease, enable earlier intervention, and guide therapy," Jay Flatley, Illumina president and CEO, said in a statement.
 
Terms of the agreement call for Illumina to supply its VeraCode technology and other reagents while ReaMetrix will develop, validate, and market the panels.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.